US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Articles published by Phathom Pharmaceuticals

< Previous 1 2 3 Next >
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Provides Update on FDA Litigation
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
< Previous 1 2 3 Next >